Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT-101 for pediatric myopia progression
NL-OMON51907Phase 3Withdrawn
- Sponsor
- Ocumension Biotech
- Start
- Oct 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trabedersen in myopia, sponsored by Ocumension Biotech. Primary endpoint: Percentage of subjects with progressive myopia at Month 36. Planned start Oct 2021; status: withdrawn.
02
Drugs
trabedersen
03
Conditions
myopia
Beyond the preview
Go deeper on NL-OMON51907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51907.